1.
An injectable nanoparticle generator enhances delivery of cancer therapeutics
by Xu, Rong
Nature biotechnology, 2016-04, Vol.34 (4), p.414-418
2.
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study...
by Borchmann, Peter
The Lancet (British edition), 2017-12-23, Vol.390 (10114), p.2790-2802
3.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
by Tap, William D, Dr
The Lancet (British edition), 2016, Vol.388 (10043), p.488-497
4.
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-...
by Tap, William D
The lancet oncology, 2017-08, Vol.18 (8), p.1089-1103
5.
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
by Engert, Andreas, MD
The Lancet (British edition), 2012-05-12, Vol.379 (9828), p.1791-1799
6.
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymp...
by Younes, Anas, Prof
The lancet oncology, 2014, Vol.15 (9), p.1019-1026
7.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a r...
by Hermine, Olivier, Prof
The Lancet (British edition), 2016, Vol.388 (10044), p.565-575
8.
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
by Sistigu, Antonella
Nature Medicine, 2014-11, Vol.20 (11), p.1301-1309
9.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retro...
by Albain, Kathy S, Prof
The lancet oncology, 2010, Vol.11 (1), p.55-65
10.
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre pha...
by Trappe, Ralf, Dr
The lancet oncology, 2012, Vol.13 (2), p.196-206
11.
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
by Sasisekharan, Ram
Nature, 2005-07-28, Vol.436 (7050), p.568-572
12.
Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes
by Yang, Yiyi
Nanotechnology, 2013-10-11, Vol.24 (40), p.405101-405101
13.
Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells
by Eid, Safaa Yehia
Phytomedicine (Stuttgart), 2012-11-15, Vol.19 (14), p.1288-1297
14.
Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells
by González-Fernández, Yolanda
Cancer letters, 2016, Vol.388, p.262-268
15.
The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review
by Ashaye, Ajibade O
Future oncology (London, England), 2022-02-01, Vol.18 (4), p.519-535
16.
Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft
by Mittal, Anil
Phytomedicine (Stuttgart), 2014-02-15, Vol.21 (3), p.340-347
17.
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON...
by The International Collaborative Ovarian Neoplasm (ICON) Group
The Lancet (British edition), 2002, Vol.360 (9332), p.505-515
18.
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
by Poon, Ronnie TP
Future oncology (London, England), 2011-08-01, Vol.7 (8), p.937-945
19.
Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone
by Wu, Peng Yan, BM
Human pathology, 2014, Vol.45 (8), p.1664-1673
20.
Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients
by Zinzani, Pier Luigi
European journal of nuclear medicine and molecular imaging, 2011-09-06, Vol.39 (1), p.4-12
